SCHEMBL491938

SCHEMBL491938

CC(C)C[C@H](C(=O)O)c1cc(-c2ccc(C(F)(F)F)cc2)cc(-c2ccc(C(F)(F)F)cc2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 4/20 1.00
PSEN2 P49810 4/20 1.00
APH1B Q8WW43 4/20 1.00
NCSTN Q92542 4/20 1.00
APH1A Q96BI3 4/20 1.00
PSENEN Q9NZ42 4/20 1.00
APP P05067 2/20 0.55
AKR1C3 P42330 4/20 0.50
AKR1C2 P52895 4/20 0.50
FFAR1 O14842 3/20 0.44
MMP1 P03956 1/20 0.43
MMP2 P08253 1/20 0.43
MMP3 P08254 1/20 0.43
MMP7 P09237 1/20 0.43
MMP9 P14780 1/20 0.43
MMP13 P45452 1/20 0.43
PPARD Q03181 2/20 0.42
PPARA Q07869 2/20 0.42
PPARG P37231 1/20 0.42
RXRA P19793 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL491340 1.00 PSEN1 (1.00) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL491331 1.00 PSEN1 (1.00) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL491329 0.96 PSEN1 (0.92) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL491366 0.96 PSEN1 (0.92) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL491298 0.96 PSEN1 (0.92) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL491536 0.95 PSEN1 (0.90) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL491339 0.95 PSEN1 (0.90) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL11960216 0.95 PSEN1 (0.90) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL491402 0.95 PSEN1 (0.90) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL491785 0.95 PSEN1 (0.90) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250213585-A1 COMPOSITIONS AND METHODS OF A CONCOMITANT THERAPY OF ALTERNATING ELECTRIC FIELDS AND NOTCH-1 INHIBITOR SHANGHAI INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY (CN) 2025-07-03 US claimed
EP-3646872-B1 BROMOCRIPTINE FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE CAUSED BY MUTATION OF PRESENILIN 1 UNIV KYOTO (JP) 2025-08-06 EP disclosed
US-20250213585-A1 COMPOSITIONS AND METHODS OF A CONCOMITANT THERAPY OF ALTERNATING ELECTRIC FIELDS AND NOTCH-1 INHIBITOR SHANGHAI INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY (CN) 2025-07-03 US disclosed
US-20240203524-A1 INFORMATION PROCESSING METHOD, INFORMATION PROCESSING DEVICE, AND STORAGE MEDIUM KYOTO UNIVERSITY (JP) 2024-06-20 US disclosed
EP-4324922-A1 INFORMATION PROCESSING METHOD, INFORMATION PROCESSING DEVICE, AND PROGRAM Kyoto University (JP) 2024-02-21 EP disclosed
CN-117136234-A Information processing method, information processing device, and program 国立大学法人京都大学 2023-11-28 CN disclosed
US-11554116-B2 Agent for preventing and/or treating alzheimer's disease KYOTO UNIVERSITY (JP) 2023-01-17 US disclosed
WO-2022220236-A1 INFORMATION PROCESSING METHOD, INFORMATION PROCESSING DEVICE, AND PROGRAM 国立大学法人京都大学 2022-10-20 WO disclosed
US-20220192984-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS Frequency Therapeutics, Inc. 2022-06-23 US disclosed
US-20220175776-A1 COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS Frequency Therapeutics, Inc. (US) 2022-06-09 US disclosed
US-8106236-B2 Triaryl compounds and derivates thereof ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2012-01-31 US disclosed
US-8106236-B2 Triaryl compounds and derivates thereof ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2012-01-31 US disclosed
US-20090306392-A1 GSM INTERMEDIATES JANSSEN PHARMACEUTICA N.V. (BE) 2009-12-10 US disclosed
US-20090306392-A1 GSM INTERMEDIATES JANSSEN PHARMACEUTICA N.V. (BE) 2009-12-10 US disclosed
US-20090306392-A1 GSM INTERMEDIATES JANSSEN PHARMACEUTICA N.V. (BE) 2009-12-10 US disclosed
WO-2009052341-A1 GSM INTERMEDIATES JANSSEN PHARMACEUTICA, N.V. (BE) 2009-04-23 WO disclosed
WO-2007124351-A1 TERPHENYL DERIVATIVES FOR TREATMENT OF ALZHEIMER' S DISEASE ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2007-11-01 WO disclosed
US-20070254957-A1 TRIARYL COMPOUNDS AND DERIVATES THEREOF ORTHO-MCNEIL PHARMACEUTICAL, INC. 2007-11-01 US disclosed
US-20070254957-A1 TRIARYL COMPOUNDS AND DERIVATES THEREOF ORTHO-MCNEIL PHARMACEUTICAL, INC. 2007-11-01 US disclosed
US-20070254957-A1 TRIARYL COMPOUNDS AND DERIVATES THEREOF ORTHO-MCNEIL PHARMACEUTICAL, INC. 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306392-A1 GSM INTERMEDIATES BACE1, GSAP, PSEN1 PSEN1 3/4885PSEN2 5/4885APH1B 8/4885
US-20220175776-A1 COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS HES1, SHH, HDAC11 PSEN1 98/4885PSEN2 45/4885APH1B 63/4885
US-20070254957-A1 TRIARYL COMPOUNDS AND DERIVATES THEREOF BACE1, BACE2, APP PSEN1 4/4885PSEN2 5/4885APH1B 12/4885
US-11554116-B2 Agent for preventing and/or treating alzheimer's disease PSEN1, APP, PSEN2 PSEN1 1/4885PSEN2 3/4885APH1B 88/4885
US-20220192984-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS OTC, EXOSC5, ENTPD5 PSEN1 223/4885PSEN2 168/4885APH1B 1400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.